Table 1.
Demographic, Clinical and Pathological Characteristics of Study Participants according to Statin Use
| Characteristic | All participants (n=539) | Statin Users * (n=258, 47.9%) | Non-Statin Users (n=281, 52.1%) | a value |
|---|---|---|---|---|
| Age at survey, Mean (SD) | 64.5 (9.4) | 66.5 (9.1) | 62.6 (9.3) | <0.001c |
| Age at surgery, Mean (SD) | 56.5 (7.6) | 58.0 (7.4) | 55.2 (7.6) | <0.001c |
| Follow-Up Time (months), Mean (SD) | 94.9 (56.6) | 101.5 (56.5) | 88.8 (56.2) | 0.009c |
| Most Recent PSA Test Value, Mean (SD) | 2.1 (19.1) | 1.37 (13.4) | 2.8 (23.0) | 0.44c |
| Race, No. (%) | ||||
| White | 523 (97.0) | 249 (96.5) | 274 (97.5) | 0.83 b |
| African-American | 13 (2.4) | 7 (2.5) | 6 (2.1) | |
| Other | 3 (0.56) | 2 (1.0) | 1 (0.4) | |
| PC affected relatives, No (%) | ||||
| 0 | 46 (8.6) | |||
| 1 | 212 (39.3) | |||
| 2 | 261 (48.4) | |||
| ≥3 | 20 (3.7) | |||
| BMI < 25.0 kg/m2, No. (%) | 148 (27.5) | 53 (20.5) | 95 (33.8) | 0.003 a |
| BMI 25.0–29.9 kg/m2 | 305 (56.6) | 159 (61.6) | 146 (52.0) | |
| BMI ≥ 30 kg/m2 | 86 (16.0) | 46 (17.8) | 40 (14.2) | |
| Lipophilic Statin Users, No. (%) | 196 (36.4) | n/a | ---- | |
| Hyrdrophilic Statin Users | 51 (9.5) | n/a | ||
| Current NSAID User, No. (%) | 270 (50.1) | 156 (60.5) | 114 (40.6) | <0.001 a |
| Non-user | 269 (49.9) | 102 (39.5) | 167 (59.4) | |
| Gleason Grade**, No (%) | ||||
| ≤6 | 240 (44.5) | 116 (45.0) | 124 (44.1) | 0.87 a |
| 7 | 180 (33.4) | 83 (32.2) | 97 (34.5) | |
| 8–10 | 94 (17.4) | 47 (18.2) | 47 (16.8) | |
| Unknown | 25 (4.7) | 12 (4.6) | 13 (4.6) | |
| Pre-Operative PSA, Mean (SD)§ | 7.5 (9.7) | 7.9 (10.2) | 7.1 (9.1) | 0.38c |
| Prostatectomy Year categories, No (%) | ||||
| < 2000 | 190 (35.2) | 107 (41.5) | 83 (29.5) | 0.004 a |
| 2000 – 2009 | 349 (64.8) | 151 (58.5) | 198 (70.5) | |
| Pathologic Stage, No. (%) | ||||
| T2a | 74 (13.7) | 25 (9.7) | 49 (17.4) | 0.05a |
| T2b | 294 (54.5) | 145 (56.2) | 149 (53.0) | |
| T3 | 113 (21.0) | 54 (20.9) | 59 (21.0) | |
| Unknown | 58 (10.8) | 34 (13.2) | 24 (8.5) | |
| Duration of Statin Use, months, Mean (SD) | 86.5 (57.5) | n/a | --- | |
*
Ever users
**
Pathological Gleason Grade except 20 observations where pathological Gleason was missing and biopsy Gleason was substituted
***
Refers to male relatives enrolled in PCGP
§
Pre-diagnostic PSA missing for 58 subjects
a
P value obtained using the Chi-square test,
b
p value obtained using Fisher’s exact test,
c
p value obtained from Student’s t test